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The focus of this review is to provide an update on the progress of microRNAs (miRNAs)
as potential biomarkers for lung cancer. miRNAs are single-stranded, small non-coding
RNAs that regulate gene expression and show tissue-specific signatures. Accumulating
evidence indicates that miRNA expression patterns represent the in vivo status in physi-
ology and disease. Moreover, miRNAs are stable in serum and other clinically convenient
and available tissue sources, so they are being developed as biomarkers for cancer and
other diseases. Cancer is currently the primary driver of the field, but miRNA biomarkers
are being developed for many other diseases such as cardiovascular and central nervous
system diseases. Here, we examine the framework and scope of the miRNA landscape as
it specifically relates to the translation of miRNA expression patterns/signatures into bio-
markers for developing diagnostics for lung cancer. We focus on examining tumor cytosol
miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer, the connections among these
miRNAs, and the potential of miRNA biomarkers for the development of diagnostics. In
lung cancer, miRNAs have been studied in both cell populations and in the circulation.
However, a major challenge is to develop biomarkers to monitor cancer development and
to identify circulating miRNAs that are linked to cancer stage. Importantly, the fact that
miRNAs can be successfully harvested from biological fluids allows for the development
of biofluid biopsies, in which miRNAs as circulating biomarkers can be captured and ana-
lyzed ex vivo. Our hope is that these minimally invasive entities provide a window to the
in vivo milieu of the patients without the need for costly, complex invasive procedures,
rapidly moving miRNAs from research to the clinic.
Keywords: microRNA, biomarker, lung cancer
INTRODUCTION
Lung cancer is the most common type of cancer worldwide. It
is estimated that there are 430,090 men and women living in the
United States with a history of lung cancer, and that an additional
224,210 cases will be diagnosed in 2014 (1). Lung cancer is also the
leading cause of cancer-related death (2). Because of the lack of val-
idated population-based screening procedures, most patients with
lung cancer are diagnosed at an advanced stage. Consequently, the
overall 5-year survival rate is only 15% (3). Therefore, there is an
urgent need to identify reliable biomarkers of lung cancer, which
can then be used for improving accuracy of diagnosis, predicting
prognosis, and monitoring disease progression and response to
therapy.
MicroRNAs (miRNAs) are small, non-coding RNAs, 19–24
nucleotides in length. They negatively regulate the expression
of multiple genes either by inducing translational silencing or
by causing the degradation of messenger RNAs (mRNAs) of
the targeted gene, both via incomplete base-pairing to a com-
plementary sequence in the 3′-untranslated region (UTR) (4).
Since the discovery of the first miRNA, lin-4, in Caenorhab-
ditis elegans (5), more than 1,800 human precursor miRNAs
have been characterized (6). The accumulating data indicate that
miRNAs play important roles in tumorigenesis, metastasis, and
drug responsiveness in lung cancer, and can be potential biomark-
ers for lung cancer (7, 8). Current research has found that the
miRNAs can not only be detected in tumor tissues but also in
body fluids and even in some extracellular organelles, such as exo-
somes, all of which have the potential to serve as biomarkers for
lung cancer. In this article, we summarize the progress on miR-
NAs originating from three different sources (tumor tissues, body
fluids, and exosomes) as biomarkers for lung cancer.
THE TUMOR CYTOSOL miRNAs, FLUID miRNAs, AND
EXOSOME miRNAs IN LUNG CANCER
THE TUMOR CYTOSOL miRNAs IN LUNG CANCER
Many factors, including variations of chromatin, epigenetic fac-
tors, hypoxia, and changes in hormone levels, can affect the expres-
sion profiles of tumor cytosolic miRNAs. Differences between
miRNAs in tumor tissues and normal tissues have been studied
extensively and profoundly, and data collected from these studies
indicate that miRNAs are involved in several critical processes of
lung cancer including the initiation, metastasis, and drug response.
In 2004, Takamizawa et al. (9) identified the first miRNA family,
let-7, which was associated with the tumorigenesis of lung cancer.
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In their study, they found that introduction of let-7a and let-7f
isoforms into A549 cells, a lung adenocarcinoma cell line with
low baseline levels of let-7 expression, significantly inhibited the
growth of A549 cells. This was further validated clinically, where
significantly shorter patient survival after diagnosis was associated
with reduced let-7 expression. Subsequently, many targets of let-
7 have been identified, including the RAS family (10), HMGA2
(10–12), c-Myc (13, 14), CDC25A, CDK6, and Cyclin D2 (15),
which elucidated the mechanisms by which let-7 exerts its func-
tion in tumorigenesis. Since then, many miRNAs were identified
as oncogenes or tumor suppressor genes, such as miR-17–92 (16,
17), miR-218 (18), miR-21 (19), and miR-34 family (miR-34a and
miR-34b/c) (20–24).
MicroRNAs not only play pivotal role in tumorigenesis of
lung cancer but also are involved in tumor metastasis. Several
miRNAs including miR-17–92 (25–28), miR-200 family of miR-
NAs (miR-200a, miR-200b, miR-200c, miR-141, and miR-429)
(29), miR-125a-3p/5p (30), miR-21 (31), and miR-106b-25 clus-
ter (miR-106b and miR-93) (32) are reported to be related to the
metastasis of lung cancer.
MicroRNAs are also involved in the drug responsiveness of lung
cancer cells. It was reported that overexpression of miR-181b could
sensitize A549/Cisplatin (CDDP) cells to CDDP-induced apopto-
sis by decreasing the levels of the anti-apoptotic protein BCL2 (33).
Additionally, miR-181a and miR-630 were reported to be modu-
lators of CDDP response in non-small-cell lung cancer (NSCLC)
A549 cells (34). In contrast, down-regulation of miR-17-5p expres-
sion was associated with paclitaxel resistance by up-regulation of
the autophagic protein Beclin 1 (BECN1) expression in NSCLC
(35). Similarly, let-7a, miR-126, and miR-145 could sensitize the
responsiveness of the large-cell cancer cell line H460 and A549
cells to Gefitinib (36).
BODY FLUID miRNAs IN LUNG CANCER
In addition to tumor tissues, miRNAs are also found in body fluids
such as blood, serum, plasma, urine, and cerebrospinal fluid (CSF),
as well as in sputum, saliva, and bronchoalveolar lavage (BAL) (37,
38). Several studies indicate that body fluid miRNAs are stable even
under extreme conditions, such as repeated freeze-thaw cycles and
extreme pHs (e.g., pH= 1 or pH= 13). This feature makes body
fluid miRNAs suitable biomarkers for clinical detection (39).
Chen et al. showed that there is a distinct difference between
the profile of miRNAs found in sera of healthy individuals and
NSCLC patients. Compared to healthy sera, the expressions of 28
different miRNAs were down-regulated and 63 different miRNAs
were up-regulated in lung cancer patients. The expression levels
of miRNA-25 and miRNA-223, which exhibited the most robust
difference in the profile, were further studied in the sera from 152
lung cancer patients and 75 healthy subjects, showing that both of
the miRNAs were indeed highly expressed in cancer patient sera.
These results indicated that miRNA-25 and miRNA-223 could be
used as potential diagnosis biomarkers for NSCLC (40).
Several other miRNAs, including miR-141, miR-155, miR-1254,
and miR-574-5p, were identified as potential early diagnostic bio-
markers (41, 42). A recent meta-analysis indicated that the early
diagnostic value of circulating miR-21 is much better than the
plasma miR-21 (43). Roth et al. found that circulating levels of
miR-361-3p and miR-625* could be used as blood-based mark-
ers for differentiating malignant lung tumors from benign lung
tumors (44).
Body fluid miRNAs, especially the circulating miRNAs, can also
be promising biomarkers for metastasis and survival time indica-
tion. Roth et al. found that high expression levels of miRNA-10b
were highly associated with positive lymph node metastasis in lung
cancer (41). Hu et al. investigated the circulating miRNA in 303
lung cancer patients and found that the concentrations of 11 miR-
NAs were elevated more than fivefolds in patients with shorter
survival times compared to those whom survived significantly
longer. In addition, miR-486, miR-30d, miR-1, and miR-499 were
identified as disease fingerprints to predict overall survival in those
patients (45). Boeri et al. showed that plasma levels of miR-155,
miR-197, and miR-182 could serve as non-invasive biomarkers for
early detection and diagnosis of lung cancer. These miRNAs were
shown to be significantly elevated in the plasma of the lung cancer
patients compared to the cancer free control subjects by greater
than 10-folds, and could help discriminate the two groups (46).
EXOSOMAL miRNAs AND LUNG CANCER
Exosomal miRNAs, strictly speaking, are also body fluid miRNAs.
However, in contrast to the miRNAs circulating freely in the body
fluid, exosomal miRNAs are encapsulated in the cell organelles
called the exosomes, which are small (30–90 nm) extracellular vesi-
cles derived from the multivesicular body (MVB) sorting pathway
(47). Numerous studies indicate that the expression of miRNAs in
exosomes is different in the normal condition and in pathological
conditions such as tumor.
Riccardo and colleagues screened 742 miRNAs in circulating
exosomes and selected 4 miRNAs (miR-378a, miR-379, miR-139-
5p, and miR-200b-5p) as screening markers for segregating lung
adenocarcinoma and carcinomas patients from healthy former
smokers. They also identified six miRNAs (miR-151a-5p, miR-
30a-3p, miR-200b-5p, miR-629, miR-100, and miR-154-3p) for
segregating lung adenocarcinoma patients and lung granuloma
patients (48).
Guilherme et al. compare 12 specific miRNAs (miR-17-3p,
miR-21, miR-106a, miR-146, miR-155, miR-191, miR-192, miR-
203, miR-205, miR-210, miR-212, and miR-214) in peripheral
circulation exosome-derived miRNAs and tumor-derived miRNAs
in lung cancer patients and healthy people. The results showed that
there was no significant difference between peripheral circulation
miRNA-derived exosomes and miRNA-derived tumors, and thus
the exosome-derived miRNAs can be used as biomarkers for lung
cancer (49).
Clearly, a number of specific miRNAs or their families show
clinical associations in lung cancer and potential values in cancer
stages in clinic (Table 1).
THE ISOLATION AND DETECTION OF TUMOR CYTOSOL
miRNAs, FLUID miRNAs, AND EXOSOME miRNAs
Tumor cytosol miRNAs can be isolated from fresh tumor tissues
or stored formalin-fixed paraffin embedded (FFPE) tissues with
Trizol or the conventional phenol/chloroform extraction.
Compared to miRNAs isolated from tumor tissues, the isolation
of miRNAs from body fluids requires careful handling in order to
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Table 1 | Selected microRNA signatures in lung cancer and their potential value in clinic.
miRNA Location Signature Potential value in clinic Reference
let-7 Tumor tissues ↓ Diagnosis marker (7)
miR-17-92 ↑ Diagnosis marker (14, 15)
miR-218 ↓ Diagnosis marker (16)
miR-21 ↑ Diagnosis marker and metastasis marker (17, 29)
miR-34a miR-34b/c ↓ Diagnosis marker (18–22)
miR-200 family ↑ Metastasis marker (27)
miR-125a-3p/5p ↓ Pathological stage indicator and metastasis marker (28)
miR-106b-25 cluster ↑ Diagnosis marker (30)
miR-181b ↑ Predictor for drug resistance to Cisplatin (31, 32)
miR-181a
miR-630
miR-17-5p ↑ Predictor for drug resistance to paclitaxel (33)
miR-145 ↑ Predictor for drug resistance to Gefitinib (34)
miR-25 Body fluids ↑ Early diagnostic marker (38)
miR-223 ↑ Early diagnostic marker (38)
miR-141 ↑ Early diagnostic marker (39)
miR-155 ↑ Early diagnostic marker (40)
miR-1254 ↑ Early diagnostic marker (41)
miR-574-5p ↑
miR-361-3p ↑ Indicator for malignant lung tumors vs benign lung tumors (42)
miR-625* ↑
miRNA-10b ↑ Indicator for positive lymph node metastasis (43)
miR-486 ↑ Predictor for overall survival (44)
miR-30d
miR-1
miR-499
miR-197 ↑ Diagnosis marker for lung cancer patients vs normal people (41)
miR-182
miR-378a Exosomes ↑ Diagnosis marker for lung adenocarcinoma and carcinomas
patients vs healthy former smokers
(46)
miR-379
miR-139-5p
miR-200b-5p
miR-151a-5p ↑ Diagnosis marker for the lung adenocarcinoma patients vs
lung granuloma patients
(46)
miR-30a-3p
miR-200b-5p
miR-629 ↑ Early diagnostic marker (47)
miR-100
miR-154-3p
avoid the contaminations of proteins in the body fluids. Chen et al.
used phenol/chloroform to remove the serum proteins after using
the Trizol for isolating miRNAs from serum (40). Researchers have
also added proteinase K to the body fluids during extraction of the
miRNAs (50). There are also commercially available kits for isola-
tion the body fluid miRNAs such as the PARIs Kit and PAXGene
Blood miRNA Kit (Qiagen). The conventional detection method
is also applicable for body fluid miRNAs (51).
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For detection of exosomal miRNAs, exosomes have to be har-
vested. The commonly used methods for isolation of exosomes
include ultracentrifugation (52) and polymer-based Exoquick
reagent (System Bioscience, Inc.) (53). The exosomes can be
identified by Western-blot analysis with the two commonly used
exosomal markers, the tetraspanin molecule CD63 and tumor
susceptibility gene TSG 101 (54).
The actual detection of tumor cytosol miRNAs, fluid miRNAs,
and exosome miRNAs use similar strategies such as Northern blot,
RT-PCR, miRNA array, or next generation sequence (NGS) (55).
Although the procedures for isolation of miRNAs from body
fluids or exosomes are relatively more complex than isolation
of miRNAs from tumor tissues, miRNAs from body fluids or
exosomes are considered as better biomarkers for lung cancers
because they involve non-invasive procedures compared biopsies
for extracting tumor-derived miRNAs. Another advantage of using
miRNAs from body fluids or exosomes as biomarkers in lung
cancer is that once potential biomarkers are identified, methods
can be optimized to detect these specific miRNAs for use in larger
studies and every-day practice (Table 2).
THE CONNECTIONS AMONG TUMOR CYTOSOL miRNAs,
FLUID miRNAs, AND EXOSOME miRNAs
The maturation of miRNAs have been studied extensively and
profoundly, and the well-accepted model is that the DNA coding
miRNAs are transcribed into the primary miRNAs (pri-miRNAs),
and then the pri-miRNAs are processed by Drosha (an RNase type
III endonuclease) and specific cofactors to generate the precur-
sor miRNAs (pre-miRNAs). Pre-miRNAs are transported from
nucleus into cytoplasm where they undergo processing by Dicer
and various cofactors to for mature miRNAs (56). But how the
mature miRNAs enter into body fluids and what is the relation-
ship between body fluid miRNAs and exosome miRNAs are still
not clear. There are three possible ways for miRNAs to enter body
Table 2 |The isolation and detection of tumor cytosol, body fluid and exosome miRNAs.
Classification Tumor cytosol miRNAs Body fluid miRNAs Exosome miRNAs
Sources Fresh tumor tissues or FFPE tissues Whole blood, serum, plasma, urine, CSF, sputum, saliva, or BAL
Special sample process
for miRNA isolation
None Need to avoid protein contamination Need to isolate exosomes
Complexity of isolation + ++ +++
Detection qRT-PCR, Northern blot, NGS, microarray
Invasiveness Yes None None
Main function Diagnosis, prognosis and therapy Early diagnosis and prognosis Early diagnosis, prognosis
and drug transportation
FFPE, formalin-fixed paraffin embedded; CSF, cerebrospinal fluid; BAL, bronchoalveolar lavage; NGS, next generation sequence.
FIGURE 1 |The connection of tumor tissue miRNA, body fluid miRNA, and exosome miRNA.
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fluids. First, the tumor cells in the primary location “secret” miR-
NAs, which combined with Ago2 and GW182 to enter body fluids
(57, 58). Second, the miRNAs in the primary tumor cells are pack-
aged into membranous vesicles (MVs) or exosomes and then enter
into body fluids (59). However, it is still not clear if the incorpora-
tion of miRNAs into exosomes occurs at the pre-miRNA or mature
miRNA level. Recently, Villarroya-Beltri et al. reported that exo-
somes contain mature miRNAs (60). Third, the tumor cells or
other cells in body fluids directly release their cytosol miRNAs
into body fluids after apoptosis (61) (Figure 1).
Currently, there is no consensus regarding the relationships
between exosomal miRNAs and the body fluid miRNAs, espe-
cially the whole blood miRNAs. Several studies have indicated
that the majority of miRNAs found in plasma and serum are
present primarily outside the exosomes (62, 63), while other stud-
ies found that miRNAs in serum and saliva exist primarily inside
the exosomes (54).
CONCLUSION
Over the last decade, great progress has been made in the research
of miRNAs and lung cancer. Several miRNAs with differential
expression patterns in lung cancer tissues compared to normal
tissues have been identified. Furthermore, aberrant expression
patterns of miRNAs in lung cancer patients can not only be
detected in tumor tissues but also in body fluids and extracel-
lular organelles such as exosomes. All these studies give weight to
the conclusion that miRNAs are promising biomarkers for diag-
nosis and prediction, as well as targets of potential therapeutics
for lung cancer. Yet, before they can be effectively integrated into
the field of clinical oncology, there are several issues that need to
be addressed: (1) Using miRNA array analysis, it is easy to find
numerous miRNA candidates whose expressions vary in lung can-
cer tissue compared to the normal tissue, or whose expressions
vary in lung cancer patients body fluids and exosomes compared
to the healthy persons. However, there is still no gold standard to
evaluate meaningful candidates. It remains a challenge to increase
the accuracy of the results from miRNA array analysis and vali-
date meaningful candidates in an efficient manner. (2) Compared
to tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs
have attracted more attention as potential diagnostic markers for
lung cancer, but there is no standard method for isolating these
two kinds of miRNAs, and no reliable endogenous control for eval-
uation. (3) The quality control of the normal healthy tissue and
fluid sample collections is also a key issue in the field, and obtain-
ing a near perfect control at the nano-scale currently remains a
major challenge. (4) The up-surging new information in this area
brings more and more potential miRNA candidates for lung can-
cer, but how to interpret and integrate all the information into
a network of knowledge for their clinical use as diagnostic and
prognostic biomarkers and as potential therapeutic targets repre-
sents another attractive area for future investigation. Overall, the
study of miRNAs offers a new and exciting angle for us to under-
stand the molecular mechanisms of lung cancer biology. Further
studies could provide more accurate biomarkers for both diagno-
sis and prediction, as well as improved strategies for lung cancer
treatment.
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